J Clin Oncol: Sacituzumab govitecan in endocrine-resistant HR+/HER2– advanced breast cancer

The prognosis of patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) endocrine-resistant metastatic breast cancer treated with sequential single-agent chemotherapy is poor

This study is a global, randomized Phase 3 study to compare SG with clinician's choice of chemotherapy (Eribulin, vinorelbine, capecitabine, or gemcitabine) in endocrine-resistant HR+/HER2- locally recurrent disease Efficacy in patients with inoperable or metastatic breast cancer

A total of 543 patients were recruited, randomized to SG (n=272) or chemotherapy (n=271), median age was 56 years, 95% of patients had visceral metastases, and 99% had previously treated cells Cyclin-dependent kinase 4/6 inhibitor

Grade 3 or higher treatment-related adverse events (SG vs chemotherapy) were neutropenia (51% vs 38%) and diarrhea (9% vs 1%)

Compared with chemotherapy, SG demonstrated a significant PFS benefit with a manageable safety profile in patients with previously multi-treated, endocrine-resistant HR+/HER2- advanced breast cancer

Original source:

Rugo Hope S,Bardia Aditya,Marmé Frederik et al.